Literature DB >> 28324240

Neurocognitive profiles in MSUD school-age patients.

Juliette Bouchereau1, Julie Leduc-Leballeur1, Samia Pichard1, Apolline Imbard2,3, Jean-François Benoist2,3, Marie-Thérèse Abi Warde4, Jean-Baptiste Arnoux4, Valérie Barbier4, Anaïs Brassier4, Pierre Broué5, Aline Cano6, Brigitte Chabrol6, Gilles Damon7, Claire Gay7, Isabelle Guillain8, Florence Habarou9,10, Delphine Lamireau11, Chris Ottolenghi9,10, Laetitia Paermentier6, Frédérique Sabourdy12,13, Guy Touati5, Hélène Ogier de Baulny1, Pascale de Lonlay4,10, Manuel Schiff14,15.   

Abstract

Maple syrup urine disease (MSUD), an inborn error of amino acids catabolism is characterized by accumulation of branched chain amino acids (BCAAs) leucine, isoleucine, valine and their corresponding alpha-ketoacids. Impact on the cognitive development has been reported historically, with developmental delays of varying degree. Currently, earlier diagnosis and improved management allow a better neurodevelopment, without requirement of special education. However, specific impairments can be observed, and so far, results of detailed neurocognitive assessments are not available. The aim of this study was to analyse neurocognitive profiles of French MSUD patients. This was a multicentre retrospective study on MSUD patients who underwent neurocognitive evaluation at primary school age. Twenty-one patients with classical neonatal onset MSUD were included. The patients' mean age at the time of evaluation was 8.7 years. The mean intellectual quotient (IQ) score was in the normal range (95.1 ± 12.6). In a subset of eight patients, a consistent developmental pattern of higher verbal than performance IQ was observed (mean of the difference 25.7 ± 8.7, p < 0.0001). No correlation could be established between this pattern and long-term metabolic balance (BCAA blood levels), or severity of acute metabolic imbalances, or leucine blood levels at diagnosis and time to toxin removal procedure. These data show that some MSUD patients may exhibit an abnormal neurocognitive profile with higher verbal than performance abilities. This might suggest an executive dysfunction disorder that would need to be further investigated by specialized testing. This pattern is important to detect in MSUD, as appropriate neuropsychological treatment strategies should be proposed.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28324240     DOI: 10.1007/s10545-017-0033-7

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  32 in total

1.  Impact of longitudinal plasma leucine levels on the intellectual outcome in patients with classic MSUD.

Authors:  Björn Hoffmann; Christoph Helbling; Peter Schadewaldt; Udo Wendel
Journal:  Pediatr Res       Date:  2005-12-02       Impact factor: 3.756

2.  Genome instability in Maple Syrup Urine Disease correlates with impaired mitochondrial biogenesis.

Authors:  Janne M Strand; Ragnhild Skinnes; Katja Scheffler; Terje Rootvelt; Berit Woldseth; Magnar Bjørås; Lars Eide
Journal:  Metabolism       Date:  2014-05-09       Impact factor: 8.694

3.  Neurocognitive profile in a case of maple syrup urine disease.

Authors:  Karin S Walsh; Megan N Scott
Journal:  Clin Neuropsychol       Date:  2010-03-02       Impact factor: 3.535

4.  Neurocognitive and neuroimaging outcome of early treated young adult PKU patients: A longitudinal study.

Authors:  Francesca Nardecchia; Filippo Manti; Flavia Chiarotti; Claudia Carducci; Carla Carducci; Vincenzo Leuzzi
Journal:  Mol Genet Metab       Date:  2015-04-29       Impact factor: 4.797

5.  Twenty-five years of research on neurocognitive outcomes in early-treated phenylketonuria: intelligence and executive function.

Authors:  Kathryn DeRoche; Marilyn Welsh
Journal:  Dev Neuropsychol       Date:  2008       Impact factor: 2.253

6.  Biochemical correlates of neuropsychiatric illness in maple syrup urine disease.

Authors:  Emilie R Muelly; Gregory J Moore; Scott C Bunce; Julie Mack; Don C Bigler; D Holmes Morton; Kevin A Strauss
Journal:  J Clin Invest       Date:  2013-03-08       Impact factor: 14.808

Review 7.  A comparison of phenylketonuria with attention deficit hyperactivity disorder: do markedly different aetiologies deliver common phenotypes?

Authors:  M Stevenson; N McNaughton
Journal:  Brain Res Bull       Date:  2013-10-16       Impact factor: 4.077

8.  Nutrition management guideline for maple syrup urine disease: an evidence- and consensus-based approach.

Authors:  Dianne M Frazier; Courtney Allgeier; Caroline Homer; Barbara J Marriage; Beth Ogata; Frances Rohr; Patricia L Splett; Adrya Stembridge; Rani H Singh
Journal:  Mol Genet Metab       Date:  2014-05-17       Impact factor: 4.797

Review 9.  Lowered concentrations of branched-chain amino acids result in impaired growth and neurological problems: insights from a branched-chain alpha-keto acid dehydrogenase complex kinase-deficient mouse model.

Authors:  Malcolm Watford
Journal:  Nutr Rev       Date:  2007-04       Impact factor: 7.110

Review 10.  Neurological damage in MSUD: the role of oxidative stress.

Authors:  Angela Sitta; Graziela S Ribas; Caroline P Mescka; Alethéa G Barschak; Moacir Wajner; Carmen R Vargas
Journal:  Cell Mol Neurobiol       Date:  2013-11-13       Impact factor: 5.046

View more
  3 in total

1.  Neonatal gene therapy achieves sustained disease rescue of maple syrup urine disease in mice.

Authors:  Clément Pontoizeau; Marcelo Simon-Sola; Clovis Gaborit; Vincent Nguyen; Irina Rotaru; Nolan Tual; Pasqualina Colella; Muriel Girard; Maria-Grazia Biferi; Jean-Baptiste Arnoux; Agnès Rötig; Chris Ottolenghi; Pascale de Lonlay; Federico Mingozzi; Marina Cavazzana; Manuel Schiff
Journal:  Nat Commun       Date:  2022-06-07       Impact factor: 17.694

2.  Discovery of Biomarker Panels for Neural Dysfunction in Inborn Errors of Amino Acid Metabolism.

Authors:  Alba-Aina Castells; Daniela Gueraldi; Rafel Balada; Alba Tristán-Noguero; Elisenda Cortès-Saladelafont; Federico Ramos; Silvia Meavilla; Mariela De Los Santos; Camila Garcia-Volpe; Roser Colomé; Maria Luz Couce; Cristina Sierra; Aida Ormazábal; Marta Batllori; Rafael Artuch; Judith Armstrong; Soledad Alcántara; Àngels Garcia-Cazorla
Journal:  Sci Rep       Date:  2019-06-24       Impact factor: 4.379

3.  Neurocognitive assessments and long-term outcome in an adult with 2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency.

Authors:  Karolina M Stepien; Philomena McCarthy; Eileen P Treacy; James J O'Byrne; Gregory M Pastores
Journal:  Mol Genet Metab Rep       Date:  2018-06-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.